Products & Pipeline

We are developing and commercializing novel Digital Therapeutics for a variety of indications including smoking cessation, major depressive disorder, schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity.

CT-100: Click Neurobehavioral Intervention (CNI) Platform

Product
Indication
Collaborator
Phase 1
Discovery
Phase 2
Dev/Pilot
Phase 3
Pivotal
Regulatory
Launch
Phase

CT-101
Clickotine®

Smoking Cessation

Launch

CT-152

Major Depressive Disorder (MDD)

Otsuka

Regulatory

CT-155

Schizophrenia

Boehringer Ingelheim

Pivotal

CT-132

Migraine

Pivotal

CT-156

Schizophrenia

Boehringer Ingelheim

Dev/Pilot

CT-102

Opioid Use Disorder (OUD)

Indivior

Discovery

CT-133

Multiple Sclerosis (MS)

Discovery

CT-171

Atopic Dermatitis

Discovery

CT-181

Obesity

Discovery

CT-191

Oncology

Discovery

CT-141
Clickadian™

Insomnia

Discovery

CT-111
Clickheart™

Acute Coronary Syndrome

Discovery

Clickotine®

CT-101

An all in one, comprehensive digital smoking cessation program

learn more

Major Depressive Disorder (MDD)

CT-152

Click is researching multiple cognitive exercises for the treatment of MDD.

Schizophrenia

CT-155

Confidential

Migraine

CT-132

Confidential

Schizophrenia

CT-156

Confidential

Clickadian™

CT-141

Clickadian is under development as a clinically-validated fully digital program for insomnia

learn more

Clickheart™

CT-111

Clickheart is under development as a clinically-validated digital program for acute coronary syndrome

learn more

Additional Products in Research & Development

CT-131
Chronic Lower
Back Pain
CT-161
Overactive
Bladder
CT-171
Atopic
Dermatitis
CT-181
Obesity
CT-191
Oncology
-
Chronic Kidney
Disease
-
Chronic Obstructive
Pulmonary Disease
-
Osteoarthritis
Products in development are investigational Digital Therapeutics not for sale. FDA has not yet evaluated the safety or effectiveness of these products.